AVPR1A — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL42152	1.00	20/20
SCHEMBL166641	1.00	20/20
SCHEMBL255943	1.00	20/20
SCHEMBL255996	1.00	20/20
SCHEMBL256004	1.00	20/20
SCHEMBL256007	1.00	20/20
SCHEMBL256567	1.00	20/20
SCHEMBL256628	1.00	20/20
SCHEMBL256643	1.00	20/20
SCHEMBL256773	1.00	20/20
SCHEMBL256949	1.00	20/20
SCHEMBL257007	1.00	20/20
SCHEMBL45462	0.89	20/20
SCHEMBL256637	0.89	20/20
SCHEMBL38380	0.88	20/20
SCHEMBL42841	0.88	20/20
SCHEMBL42369	0.86	20/20
SCHEMBL42820	0.86	20/20
SCHEMBL256627	0.86	20/20
SCHEMBL45615	0.84	20/20

Clinical trials — most relevant to AVPR1A by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Cardiac Output Response to Vasopressin Infusion In Abdominal Surgery Patients Under Mechanical Ventilation	PHASE4	COMPLETED
Diet as a Potential Treatment for Autosomal Dominant Polycystic Kidney Disease	PHASE2/PHASE3	COMPLETED
Efficacy Study of Fedovapagon for Nocturia in Men With Benign Prostatic Hyperplasia (BPH)	PHASE2/PHASE3	COMPLETED
SALT-2 Trial Study of Ascending Levels of Tolvaptan in Hyponatremia	PHASE3	COMPLETED
Study of Stroke Related Edema Treatments	PHASE2	WITHDRAWN
Efficacy and Safety of VA106483 in Elderly Males	PHASE1/PHASE2	COMPLETED
Effect of Intranasal Oxytocin on Emotion Recognition and Acute Psycho-Social Stress-induced Cortisol Increase in Patients With Central Diabetes Insipidus and Healthy Controls	PHASE2	RECRUITING
Evaluation of the Potential Effects of SSR149415 on the Hypothalamic-pituitary-adrenal Axis in Outpatients With Major Depressive Disorder	PHASE2	COMPLETED
Effects of Intranasal Oxytocin on Sexual Well-Being in Patients With Arginine Vasopressin Deficiency and Healthy Controls	PHASE2	RECRUITING
Effect of the Aquaretic Tolvaptan on Nitric Oxide System (TORA)	PHASE2	COMPLETED
Tolerability, Safety, and Activity of SRX246 in Irritable Subjects With Huntington's Disease	PHASE2	COMPLETED
Oxytocin Substitution Therapy in Patients With Central Diabetes Insipidus	PHASE2	RECRUITING
The Role of Vasopressin Antagonism on Renal Sodium Handling	PHASE1	COMPLETED
Safety Study of SRX251 Capsules in Healthy Female Volunteers	PHASE1	COMPLETED
Vasopressin vs. Epinephrine During Neonatal Cardiopulmonary Resuscitation	PHASE1	ACTIVE_NOT_RECRUITING
Dose Response Study of VA106483 in Males With Nocturia and Benign Prostatic Hypertrophy (BPH)	PHASE1	COMPLETED
VA111913 TS: First in Human Study	PHASE1	COMPLETED
Study in Healthy Male Subjects to Evaluate the Effect of Itraconazole and Rifampicin on the PK of Fedovapagon	PHASE1	COMPLETED
The Effect of Vasopressin on Glucose Regulation	nan	COMPLETED
Effect of Vasopressin on Kidney and Cardiac Function in Septic Shock	nan	UNKNOWN
Study to Evaluate if the Drug Vasopressin Protects the Kidneys for Patients Undergoing Liver Transplant	nan	COMPLETED
Effects of Intravenous [Pyr1]Apelin-13 on Healthy Volunteers With Artificially Induced SIAD	nan	COMPLETED
From Micro- to Macro-vessels : Water, Salt, Heart and Kidneys	nan	COMPLETED
Endocan and Copeptin Serum Levels in Preterm Neonates With Respiratory Distress Syndrome	nan	RECRUITING
V2 Receptor Effects on Fluid Regulation and Performance	nan	COMPLETED
Copeptin for Risk Stratification in Acute Stroke Patients: the CoRisk Study	nan	COMPLETED
Evaluation of Vasopressin in the Vessels of Ovarian Neoplasms	nan	COMPLETED
Urea for Treatment of Hyponatremia in Patients With SIAD Unresponsive to Fluid Restriction	nan	RECRUITING
Vasopressin Plasma Concentrations in Patients Receiving Exogenous Vasopressin Infusion for Septic Shock	nan	COMPLETED
Regulation of Arginine-vasopressin (AVP)	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a AVPR1A binder may also engage these)

Protein	Name	Similarity
Q9WTV9	—	1.000	Q9WTV9 →
Q9WTV8	—	0.999	Q9WTV8 →
Q62463	—	0.995	Q62463 →
P30560	—	0.993	P30560 →
P48043	—	0.991	P48043 →
P32306	—	0.979	P32306 →
Q28756	—	0.979	Q28756 →
P56449	—	0.978	P56449 →
O42329	—	0.978	O42329 →
P97926	—	0.977	P97926 →
P56494	—	0.977	P56494 →
P70536	—	0.976	P70536 →
OXTR	Oxytocin receptor	0.974	landscape →
Q90334	—	0.972	Q90334 →
Q90252	—	0.970	Q90252 →
Q90352	—	0.968	Q90352 →
AVPR1B	Vasopressin V1b receptor	0.965	landscape →
Q9WU02	—	0.962	Q9WU02 →
P48974	—	0.962	P48974 →
Q8BZP8	—	0.962	Q8BZP8 →
Q95JG1	—	0.959	Q95JG1 →
Q95MH6	—	0.959	Q95MH6 →
Q868T3	—	0.958	Q868T3 →
P32211	—	0.958	P32211 →
Q95MG6	—	0.957	Q95MG6 →
P30975	—	0.956	P30975 →
P30551	—	0.955	P30551 →
CHRM4	Muscarinic acetylcholine receptor M4	0.955	landscape →
Q5D0K2	—	0.955	Q5D0K2 →
P0C0L6	—	0.954	P0C0L6 →